Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer

Fitzmaurice, 2017, Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015, JAMA Oncol, 3, 524, 10.1001/jamaoncol.2016.5688 Aggen, 2017, Biomarkers for immunotherapy in bladder cancer: a moving target, J Immunother Cancer, 5, 94, 10.1186/s40425-017-0299-1 Robertson, 2017, Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, 171, 10.1016/j.cell.2017.09.007 Thommen, 2015, Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors, Cancer Immunol Res, 3, 1344, 10.1158/2326-6066.CIR-15-0097 Granier, 2017, Tim-3 expression on tumor-infiltrating PD-1+CD8+T cells correlates with poor clinical outcome in renal cell carcinoma, Cancer Res, 77, 1075, 10.1158/0008-5472.CAN-16-0274 Linedale, 2017, Elevated frequencies of CD8T cells expressing PD-1. CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients, PLoS One, 12, e0175755, 10.1371/journal.pone.0175755 Ghasemzadeh, 2016, New strategies in bladder cancer: a second coming for immunotherapy, Clin Cancer Res, 22, 793, 10.1158/1078-0432.CCR-15-1135 Woo, 2012, Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape, Cancer Res, 72, 917, 10.1158/0008-5472.CAN-11-1620 Sakuishi, 2010, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J Exp Med, 207, 2187, 10.1084/jem.20100643 Joyce, 2015, T cell exclusion, immune privilege, and the tumor microenvironment, Science, 348, 74, 10.1126/science.aaa6204